24/7 Market News Snapshot 13 May, 2025 – Absci Corporation Common Stock (NASDAQ:ABSI)

May 13, 2025

DENVER, Colo., 13 May, 2025 (www.247marketnews.com) – (NASDAQ:ABSI) are discussed in this article.
Absci Corporation (ABSI) has commenced trading today with a notable increase, opening at $2.91 and demonstrating a strong bullish trend with a rise of approximately 15.12%. Currently priced at $3.373, the stock has seen a trading volume of 4.40 million shares, indicating robust investor interest and positive sentiment driven by the company’s innovative biomanufacturing technologies. This surge suggests a potential breakout from established resistance levels, making it imperative for traders to monitor future price movements closely, particularly in light of overall market conditions and the company’s fundamentals, which may significantly impact ABSI’s future trajectory.

In a significant development, Absci has officially entered the clinical stage by initiating a pivotal Phase 1 trial for its flagship product, ABS-101. This milestone represents a transformative moment for the company as it executes a randomized, double-blind, placebo-controlled trial involving the administration of an engineered anti-TL1A antibody to healthy volunteers. ABS-101, developed using Absci’s generative AI platform, has shown promising preclinical results indicative of high potency and the potential for quarterly dosing, positioning it as a contender to redefine treatment paradigms for inflammatory bowel disease (IBD).

Sean McClain, Founder and CEO of Absci, remarked on the significance of this trial launch, highlighting ABS-101 as a critical advance in their therapeutic pipeline and a testament to their innovative capabilities. The trial aims to assess the safety and tolerability of ABS-101, along with evaluating its pharmacokinetics and pharmacodynamics, with interim results expected in the latter half of 2025. In addition to ABS-101, Absci is advancing a robust pipeline that includes ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia. Committed to exploiting its Integrated Drug Creation™ platform, Absci aims to revolutionize drug development and address significant unmet medical needs across various therapeutic areas.

Related news for (ABSI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.